EKF Diagnostics Holdings plc (AIM:EKF)

Market Cap	105.49M
Revenue (ttm)	50.19M
Net Income (ttm)	6.24M
Shares Out	453.73M
EPS (ttm)	0.01
PE Ratio	16.85
Forward PE	15.44
Dividend	0.01 (5.85%)
Ex-Dividend Date	n/a

Volume	2,488,303
Average Volume	750,750
Open	20.10
Previous Close	20.50
Day's Range	20.10 - 22.70
52-Week Range	18.40 - 33.80
Beta	0.49
RSI	60.99
Earnings Date	Mar 21, 2025

About EKF Diagnostics Holdings

EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, Africa, and internationally. It offers DiaSpect Tm hand-held hemoglobin analyzer; Hemo Control, a hemoglobin and hematocrit analyzer; Ultracrit, a hematocrit device; DiaSpect Hemoglobin T analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. The company also provides glucos...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1990
• Employees: 317
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: EKF

Financial Performance

In 2024, EKF Diagnostics Holdings's revenue was 50.19 million, a decrease of -4.59% compared to the previous year's 52.61 million. Earnings were 6.24 million, an increase of 165.39%.